LEGN stock climbs as analysts parse JNJ Q3 to estimate Carvykti sales (NASDAQ:LEGN)
seekingalpha.com
finance
2022-10-18 19:52:05

Hailshadow/iStock via Getty Images Legend Biotech Corporation (NASDAQ:LEGN), a company focused on cell therapies, traded sharply higher on Tuesday as Wall Street parsed Q3 2022 results from Johnson & Johnson (JNJ) to estimate sales of multiple myeloma therapy Carvykti for which the two have partnered. In December 2017, LEGN entered into an exclusive licensing deal with JNJ's Janssen unit to develop and commercialize the treatment globally. While JNJ did not directly report sales of the cell therapy, Barclays analyst Gena Wang compared the company's other oncology sales in the U.
